An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

BACKGROUND: Cabazitaxel significantly improves clinical outcomes compared with a second androgen receptor-targeted agent (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and an ARTA (abiraterone or enzalutamide), as demonstrated in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgans, Alicia K., Hutson, Thomas, Guan, Alice Kai Dan, Garcia, David, Zhou, Anna, Drea, Edward, Vogelzang, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284907/
https://www.ncbi.nlm.nih.gov/pubmed/35836170
http://dx.doi.org/10.1186/s12913-022-08274-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284907/
https://www.ncbi.nlm.nih.gov/pubmed/35836170
http://dx.doi.org/10.1186/s12913-022-08274-x

Ejemplares similares